Werewolf Therapeutics, Inc. Annual Report - How They Did This Year

I’m writing this guide to help you understand how Werewolf Therapeutics (ticker: HOWL) performed this year. Think of this as a cheat sheet to help you decide if this company fits your investment goals.

1. What does this company do?

Werewolf Therapeutics is a biotech company based in Watertown, Massachusetts. They develop "precision" cancer treatments using their PREDATOR protein engineering platform.

They create therapies—specifically INDUKINE and INDUCER molecules—that stay inactive in the bloodstream. These drugs only activate inside a tumor. This approach aims to kill cancer while sparing healthy cells. Because their treatments are still in early-stage clinical trials, the company has no products to sell and currently earns zero revenue.

2. Financial health: A critical turning point

The company is in a tough financial spot. As of December 31, 2025, they held $48.2 million in cash and investments, down from $92.5 million the year before.

In February 2026, they announced a major restructuring to save money. They are now in a "strategic review," which means they are actively seeking a buyer, a merger partner, or a company to license their technology.

To save money, they laid off 64% of their staff, leaving about 35 employees. This move costs $4.1 million in severance, which will show up in their early 2026 expenses. With a past annual cash burn over $60 million, the company needs a deal soon to survive past late 2026.

3. Major wins and challenges

It’s a mixed bag. On the science side, they have seen some promising early results:

• WTX-124: In late 2025, this molecule showed a 21% response rate in patients with advanced solid tumors who had failed other treatments.
• WTX-330: In a Phase 1 trial, this molecule helped shrink a tumor by 45% in a patient with hard-to-treat gallbladder cancer.

The Challenge: Despite these early wins, the company lacks the capital needed for the large-scale trials required for FDA approval. They have hired an advisor to help them sell the company or license their technology.

4. What this means for your investment

With a market value of roughly $39.6 million, this is a "micro-cap" stock. Because they are looking for a buyer, the stock price will likely swing wildly based on rumors or news about a potential deal.

If you own shares, you are betting that the company will be bought out. If they cannot find a buyer or a partner, they may have to sell their assets or file for bankruptcy. In that scenario, shareholders would likely lose their entire investment.

5. Key risks to watch

• Survival Risk: Auditors have raised "going concern" warnings, indicating real doubt about whether the company can stay in business for another year without a sale or new funding.
• Strategic Uncertainty: There is no guarantee they will find a buyer, or that a deal would be profitable for current shareholders.
• Clinical Failure: Their technology is still early-stage. If future data doesn't prove their drugs work better than current options, the company’s value could disappear.
• Manufacturing Hurdles: Their drugs are complex and rely on outside partners to manufacture them. Any issues at those facilities could stop their trials and hurt the company’s value.

---

Note: Werewolf Therapeutics is in a "make or break" phase. The company is actively trying to sell itself. Please be extremely cautious, as this is a high-risk situation where the company's survival is not guaranteed. Before investing, consider whether you are comfortable with the possibility of a total loss of capital in exchange for the potential upside of a buyout.